<div id="readability-page-1"><div>RADNOR, Pa., Feb. 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer &amp; Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025. CONTACT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: If you suffered Cassava losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/cassava-sciences-inc-2024?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=sava&amp;mktm=r You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. DEFENDANTS’ ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Cassava’s drug, simufilam, was not capable of abating the progression of Alzheimer’s Disease, even in mild to moderate cases; and (2) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/DkxXQ_P5Nn4 THE LEAD PLAINTIFF PROCESS: Cassava investors may, no later than February 10, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer &amp; Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer &amp; Check, LLP encourages Cassava investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/cassava-sciences-inc-2024?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=sava&amp;mktm=r ABOUT KESSLER TOPAZ MELTZER &amp; CHECK, LLP: Kessler Topaz Meltzer &amp; Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer &amp; Check, LLP. For more information about Kessler Topaz Meltzer &amp; Check, LLP please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer &amp; Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 info@ktmc.com May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RNMU5ETTFPU00yTnpNNU5UYzNJekl3TVRrek1UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RNMU5ETTFPU00yTnpNNU5UYzNJekl3TVRrek1UST0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmJhMGE1OTEtZDYyZC00YWVjLThhZGQtOGE0ZTBkZDg1ZDQ2LTEwMzA4ODU=/tiny/Kessler-Topaz-Meltzer-Check-LL.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmJhMGE1OTEtZDYyZC00YWVjLThhZGQtOGE0ZTBkZDg1ZDQ2LTEwMzA4ODU=/tiny/Kessler-Topaz-Meltzer-Check-LL.png"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/405ec490-b904-4a5e-85a7-710cdebe280d/small/ktmc-logo-rgb-jpg.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="150" height="71" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/405ec490-b904-4a5e-85a7-710cdebe280d/small/ktmc-logo-rgb-jpg.jpg"/></div></div>

SAVA

FLNA

Kessler Topaz Meltzer & Check, LLP 宣佈了投資者在 Cassava Sciences, Inc. (NASDAQ: SAVA) 中作為主要原告提起證券集體訴訟的截止日期。該訴訟在美國德克薩斯州西區地方法院提起，指控 Cassava 對其藥物 simufilam 在治療阿爾茨海默病方面的有效性做出了虛假陳述。遭受損失的投資者必須在 2024 年 2 月 7 日至 2024 年 11 月 24 日之間採取行動，截止日期為 2025 年 2 月 10 日，以參與此案

SAVA 最後期限還有 2 天：Kessler Topaz Meltzer & Check, LLP 提醒 Cassava Sciences, Inc. (SAVA) 的投資者集體訴訟的提交截止日期